A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance

Li Jiang, Ping Liu, Claudia Bank, Nicholas Renzette, Kristina Prachanronarong, Lutfu S. Yilmaz, Daniel R. Caffrey, Konstantin B. Zeldovich, Celia A. Schiffer, Timothy F. Kowalik, Jeffrey Jensen, Robert W. Finberg, Jennifer P. Wang, Daniel N A Bolon

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The therapeutic benefits of the neuraminidase (NA) inhibitor oseltamivir are dampened by the emergence of drug resistance mutations in influenza A virus (IAV). To investigate the mechanistic features that underlie resistance, we developed an approach to quantify the effects of all possible single-nucleotide substitutions introduced into important regions of NA. We determined the experimental fitness effects of 450 nucleotide mutations encoding positions both surrounding the active site and at more distant sites in an N1 strain of IAV in the presence and absence of oseltamivir. NA mutations previously known to confer oseltamivir resistance in N1 strains, including H275Y and N295S, were adaptive in the presence of drug, indicating that our experimental system captured salient features of real-world selection pressures acting on NA. We identified mutations, including several at position 223, that reduce the apparent affinity for oseltamivir in vitro. Position 223 of NA is located adjacent to a hydrophobic portion of oseltamivir that is chemically distinct from the substrate, making it a hotspot for substitutions that preferentially impact drug binding relative to substrate processing. Furthermore, two NA mutations, K221N and Y276F, each reduce susceptibility to oseltamivir by increasing NA activity without altering drug binding. These results indicate that competitive expansion of IAV in the face of drug pressure is mediated by a balance between inhibitor binding and substrate processing.

Original languageEnglish (US)
Pages (from-to)538-553
Number of pages16
JournalJournal of Molecular Biology
Volume428
Issue number3
DOIs
StatePublished - Feb 13 2016
Externally publishedYes

Fingerprint

Oseltamivir
Neuraminidase
Drug Resistance
Human Influenza
Influenza A virus
Mutation
Pharmaceutical Preparations
Nucleotides
Pressure
Catalytic Domain

Keywords

  • adaptive
  • experimental fitness
  • neuraminidase inhibitor
  • oseltamivir
  • systematic mutation

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Jiang, L., Liu, P., Bank, C., Renzette, N., Prachanronarong, K., Yilmaz, L. S., ... Bolon, D. N. A. (2016). A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance. Journal of Molecular Biology, 428(3), 538-553. https://doi.org/10.1016/j.jmb.2015.11.027

A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance. / Jiang, Li; Liu, Ping; Bank, Claudia; Renzette, Nicholas; Prachanronarong, Kristina; Yilmaz, Lutfu S.; Caffrey, Daniel R.; Zeldovich, Konstantin B.; Schiffer, Celia A.; Kowalik, Timothy F.; Jensen, Jeffrey; Finberg, Robert W.; Wang, Jennifer P.; Bolon, Daniel N A.

In: Journal of Molecular Biology, Vol. 428, No. 3, 13.02.2016, p. 538-553.

Research output: Contribution to journalArticle

Jiang, L, Liu, P, Bank, C, Renzette, N, Prachanronarong, K, Yilmaz, LS, Caffrey, DR, Zeldovich, KB, Schiffer, CA, Kowalik, TF, Jensen, J, Finberg, RW, Wang, JP & Bolon, DNA 2016, 'A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance', Journal of Molecular Biology, vol. 428, no. 3, pp. 538-553. https://doi.org/10.1016/j.jmb.2015.11.027
Jiang, Li ; Liu, Ping ; Bank, Claudia ; Renzette, Nicholas ; Prachanronarong, Kristina ; Yilmaz, Lutfu S. ; Caffrey, Daniel R. ; Zeldovich, Konstantin B. ; Schiffer, Celia A. ; Kowalik, Timothy F. ; Jensen, Jeffrey ; Finberg, Robert W. ; Wang, Jennifer P. ; Bolon, Daniel N A. / A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance. In: Journal of Molecular Biology. 2016 ; Vol. 428, No. 3. pp. 538-553.
@article{565700168e6c4a70b2c40493af8992f6,
title = "A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance",
abstract = "The therapeutic benefits of the neuraminidase (NA) inhibitor oseltamivir are dampened by the emergence of drug resistance mutations in influenza A virus (IAV). To investigate the mechanistic features that underlie resistance, we developed an approach to quantify the effects of all possible single-nucleotide substitutions introduced into important regions of NA. We determined the experimental fitness effects of 450 nucleotide mutations encoding positions both surrounding the active site and at more distant sites in an N1 strain of IAV in the presence and absence of oseltamivir. NA mutations previously known to confer oseltamivir resistance in N1 strains, including H275Y and N295S, were adaptive in the presence of drug, indicating that our experimental system captured salient features of real-world selection pressures acting on NA. We identified mutations, including several at position 223, that reduce the apparent affinity for oseltamivir in vitro. Position 223 of NA is located adjacent to a hydrophobic portion of oseltamivir that is chemically distinct from the substrate, making it a hotspot for substitutions that preferentially impact drug binding relative to substrate processing. Furthermore, two NA mutations, K221N and Y276F, each reduce susceptibility to oseltamivir by increasing NA activity without altering drug binding. These results indicate that competitive expansion of IAV in the face of drug pressure is mediated by a balance between inhibitor binding and substrate processing.",
keywords = "adaptive, experimental fitness, neuraminidase inhibitor, oseltamivir, systematic mutation",
author = "Li Jiang and Ping Liu and Claudia Bank and Nicholas Renzette and Kristina Prachanronarong and Yilmaz, {Lutfu S.} and Caffrey, {Daniel R.} and Zeldovich, {Konstantin B.} and Schiffer, {Celia A.} and Kowalik, {Timothy F.} and Jeffrey Jensen and Finberg, {Robert W.} and Wang, {Jennifer P.} and Bolon, {Daniel N A}",
year = "2016",
month = "2",
day = "13",
doi = "10.1016/j.jmb.2015.11.027",
language = "English (US)",
volume = "428",
pages = "538--553",
journal = "Journal of Molecular Biology",
issn = "0022-2836",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance

AU - Jiang, Li

AU - Liu, Ping

AU - Bank, Claudia

AU - Renzette, Nicholas

AU - Prachanronarong, Kristina

AU - Yilmaz, Lutfu S.

AU - Caffrey, Daniel R.

AU - Zeldovich, Konstantin B.

AU - Schiffer, Celia A.

AU - Kowalik, Timothy F.

AU - Jensen, Jeffrey

AU - Finberg, Robert W.

AU - Wang, Jennifer P.

AU - Bolon, Daniel N A

PY - 2016/2/13

Y1 - 2016/2/13

N2 - The therapeutic benefits of the neuraminidase (NA) inhibitor oseltamivir are dampened by the emergence of drug resistance mutations in influenza A virus (IAV). To investigate the mechanistic features that underlie resistance, we developed an approach to quantify the effects of all possible single-nucleotide substitutions introduced into important regions of NA. We determined the experimental fitness effects of 450 nucleotide mutations encoding positions both surrounding the active site and at more distant sites in an N1 strain of IAV in the presence and absence of oseltamivir. NA mutations previously known to confer oseltamivir resistance in N1 strains, including H275Y and N295S, were adaptive in the presence of drug, indicating that our experimental system captured salient features of real-world selection pressures acting on NA. We identified mutations, including several at position 223, that reduce the apparent affinity for oseltamivir in vitro. Position 223 of NA is located adjacent to a hydrophobic portion of oseltamivir that is chemically distinct from the substrate, making it a hotspot for substitutions that preferentially impact drug binding relative to substrate processing. Furthermore, two NA mutations, K221N and Y276F, each reduce susceptibility to oseltamivir by increasing NA activity without altering drug binding. These results indicate that competitive expansion of IAV in the face of drug pressure is mediated by a balance between inhibitor binding and substrate processing.

AB - The therapeutic benefits of the neuraminidase (NA) inhibitor oseltamivir are dampened by the emergence of drug resistance mutations in influenza A virus (IAV). To investigate the mechanistic features that underlie resistance, we developed an approach to quantify the effects of all possible single-nucleotide substitutions introduced into important regions of NA. We determined the experimental fitness effects of 450 nucleotide mutations encoding positions both surrounding the active site and at more distant sites in an N1 strain of IAV in the presence and absence of oseltamivir. NA mutations previously known to confer oseltamivir resistance in N1 strains, including H275Y and N295S, were adaptive in the presence of drug, indicating that our experimental system captured salient features of real-world selection pressures acting on NA. We identified mutations, including several at position 223, that reduce the apparent affinity for oseltamivir in vitro. Position 223 of NA is located adjacent to a hydrophobic portion of oseltamivir that is chemically distinct from the substrate, making it a hotspot for substitutions that preferentially impact drug binding relative to substrate processing. Furthermore, two NA mutations, K221N and Y276F, each reduce susceptibility to oseltamivir by increasing NA activity without altering drug binding. These results indicate that competitive expansion of IAV in the face of drug pressure is mediated by a balance between inhibitor binding and substrate processing.

KW - adaptive

KW - experimental fitness

KW - neuraminidase inhibitor

KW - oseltamivir

KW - systematic mutation

UR - http://www.scopus.com/inward/record.url?scp=84958759356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958759356&partnerID=8YFLogxK

U2 - 10.1016/j.jmb.2015.11.027

DO - 10.1016/j.jmb.2015.11.027

M3 - Article

C2 - 26656922

AN - SCOPUS:84958759356

VL - 428

SP - 538

EP - 553

JO - Journal of Molecular Biology

JF - Journal of Molecular Biology

SN - 0022-2836

IS - 3

ER -